Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over
Technology appraisal
Summary (source: NICE)
Reference: TA1101
Type: Technology appraisal
Published: 8 October 2025
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over is technology appraisal TA1101, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 8 October 2025. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.